Catalyst Pharmaceuticals, Inc. (CPRX)
- Previous Close
15.10 - Open
15.20 - Bid 14.70 x 100
- Ask 14.79 x 100
- Day's Range
14.73 - 15.22 - 52 Week Range
11.09 - 17.77 - Volume
990,001 - Avg. Volume
1,344,646 - Market Cap (intraday)
1.738B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
23.38 - EPS (TTM)
0.63 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.71
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
www.catalystpharma.comRecent News: CPRX
Performance Overview: CPRX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CPRX
Valuation Measures
Market Cap
1.78B
Enterprise Value
1.65B
Trailing P/E
23.98
Forward P/E
10.28
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.32
Price/Book (mrq)
4.60
Enterprise Value/Revenue
4.14
Enterprise Value/EBITDA
13.78
Financial Highlights
Profitability and Income Statement
Profit Margin
17.93%
Return on Assets (ttm)
12.83%
Return on Equity (ttm)
20.75%
Revenue (ttm)
398.2M
Net Income Avi to Common (ttm)
71.41M
Diluted EPS (ttm)
0.63
Balance Sheet and Cash Flow
Total Cash (mrq)
137.64M
Total Debt/Equity (mrq)
0.92%
Levered Free Cash Flow (ttm)
-219.49M
Research Analysis: CPRX
Company Insights: CPRX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CPRX
CPRX: Lowering target price to $16.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetCPRX: Raising target price to $17.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetCPRX: Lowering target price to $16.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetCPRX: What does Argus have to say about CPRX?
CATALYST PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target